绽妍生物由70后董事长张颖霆控股91%，前妻为一致行动人

Group 1 - The core viewpoint of the news is that Zhan Yan Biotechnology Co., Ltd. has completed its IPO counseling record with the Sichuan Securities Regulatory Bureau and plans to list on the Beijing Stock Exchange, with China International Capital Corporation as the counseling institution [1] - Zhan Yan Biotechnology was established on December 6, 2019, with a registered capital of 61.62 million yuan, focusing on the research, production, and sales of biomedical materials, dermatological skincare products, and bioactive raw materials [1] - The company has three major sub-brands: "Zhan Yan" for skin issues, "Zhan Xiao Yan" for infant skincare, and "De Fei Lin" for bioactive composite acids, targeting different demographics with product lines for skin disease auxiliary treatment and sensitive skin repair [2] Group 2 - The projected operating revenue for Zhan Yan Biotechnology is 486 million yuan in 2023 and 597 million yuan in 2024, with net profits of 68.48 million yuan and 73.50 million yuan respectively, and gross profit margins of 62.33% and 68.34% [2][3] - In 2024, the company expects to achieve an operating revenue of 597.47 million yuan and a net profit of 73.50 million yuan, with a gross profit margin of 68.34% and a weighted return on net assets of 22.39% [3] - Zhang Yingting, the controlling shareholder, directly holds 62.16% of the company's shares and, along with his associates, controls 91.22% of the voting rights [3]